Scientific intelligence record
Experience 2.0
Kisspeptin fragment
Bioactive C-terminal kisspeptin fragment that activates KISS1R and hypothalamic-pituitary-gonadal signaling.
Record status
Traceability partial
Last meaningful update: 9/20/2026
Ranked research corpus
390
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
390 matching records · ranked 2026-09-18
Page 1 of 16
Europe PMC · 2027 · PMID 42364891 · DOI 10.1016/j.cca.2026.121207
human-observational
Europe PMC · 2026 · PMID 42549827 · DOI 10.1093/ejendo/lvag134
human-interventional
Europe PMC · 2026 · PMID 40910466 · DOI 10.1080/07391102.2025.2553344
preclinical-animal
Europe PMC · 2026 · PMID 41380532 · DOI 10.1016/j.npep.2025.102580
preclinical-animal
Europe PMC · 2026 · Source ID doi:10.21203/rs.3.rs-8942588/v1 · DOI 10.21203/rs.3.rs-8942588/v1
human-interventional
Europe PMC · 2026 · PMID 42230485 · DOI 10.1007/s42000-026-00795-y
human-interventional
OpenAlex · 2026 · Source ID doi:10.5281/zenodo.22654457 · DOI 10.5281/zenodo.22654457
contextual-unclassified
OpenAlex · 2026 · Source ID doi:10.5281/zenodo.22654456 · DOI 10.5281/zenodo.22654456
contextual-unclassified
OpenAlex · 2026 · Source ID doi:10.5281/zenodo.22654284 · DOI 10.5281/zenodo.22654284
contextual-unclassified
OpenAlex · 2026 · Source ID doi:10.5281/zenodo.22654283 · DOI 10.5281/zenodo.22654283
contextual-unclassified
Europe PMC · 2026 · PMID 42292313 · DOI 10.1007/s10616-026-01005-8
preclinical-animal
Europe PMC · 2026 · PMID 41328591 · DOI 10.1002/mc.70068
preclinical-animal
Europe PMC · 2026 · PMID 41389577 · DOI 10.1016/j.compbiolchem.2025.108826
preclinical-animal
Europe PMC · 2026 · PMID 41782211 · DOI 10.1111/apha.70188
preclinical-animal
Europe PMC · 2026 · PMID 42680947 · DOI 10.1007/s12035-026-06171-6
preclinical-animal
Europe PMC · 2026 · PMID 41952615 · DOI 10.1002/mrd.70093
preclinical-animal
Europe PMC · 2026 · PMID 41955717 · DOI 10.1016/j.npep.2026.102611
preclinical-animal
Europe PMC · 2026 · PMID 42159865 · DOI 10.1007/s43440-026-00870-6
laboratory-mechanistic
Europe PMC · 2026 · PMID 42726152 · DOI 10.1007/s12012-026-10185-w
preclinical-animal
Europe PMC · 2026 · PMID 42328738 · DOI 10.1039/d6an00455e
preclinical-animal
Europe PMC · 2026 · PMID 41953732 · DOI 10.2478/jvetres-2026-0010
preclinical-animal
Europe PMC · 2026 · PMID 42707558 · DOI 10.1007/s40203-026-00726-0
preclinical-animal
Europe PMC · 2026 · PMID 42123334 · DOI 10.3390/ijms27093748
preclinical-animal
Europe PMC · 2026 · PMID 42379494 · DOI 10.1016/j.mce.2026.112854
preclinical-animal
Europe PMC · 2025 · PMID 40362219 · DOI 10.3390/ijms26093977
preclinical-animal
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.
Kisspeptin-10 evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
peptide explorer
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Fully specified molecular identity
Complete amidated decapeptide identity; schematic is not a receptor-bound conformation.
Sources: NIH PubChem — Kisspeptin-10 · reviewed 2026-09-17
APA
World Peptide Foundation. (n.d.). Kisspeptin-10 — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/kisspeptin-10
AMA / Vancouver
World Peptide Foundation. Kisspeptin-10 — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/kisspeptin-10
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
6
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
390
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
6
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Kisspeptin-10 no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasPubMed-indexed journal article; randomized controlled trial, veterinary; research support, n.i.h., extramural examining safety evaluation of kp-10 (metastin 45-54) following once daily intravenous administration for 14 days in dog. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining kisspeptin-10 inhibits ohss by suppressing vegf secretion. Machine-staged source candidate; findings and limitations require accountable review before publication.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
2014 · study · Temporal status not established
Brain research
2015 · study · Temporal status not established
Oncology reports
2015 · study · Temporal status not established
Advanced biomedical research
2017 · study · Temporal status not established
Reproduction (Cambridge, England)
2017 · study · Temporal status not established
PloS one
2017 · study · Temporal status not established
Journal of the Endocrine Society
2017 · study · Temporal status not established
PloS one
2018 · study · Temporal status not established
The Journal of endocrinology
2018 · study · Temporal status not established
Molecules (Basel, Switzerland)
2018 · study · Temporal status not established
Scientific reports
2021 · study · Temporal status not established
International journal of toxicology
2021 · study · Temporal status not established
Reproductive sciences (Thousand Oaks, Calif.)
2022 · study · Temporal status not established
Animal : an international journal of animal bioscience
2022 · study · Temporal status not established
Andrologia
2022 · study · Temporal status not established
JCI insight
2022 · study · Temporal status not established
International journal of molecular sciences
2022 · study · Temporal status not established
Genes
2023 · study · Temporal status not established
Scientific reports
2023 · study · Temporal status not established
The Journal of pathology
2024 · study · Temporal status not established
Biomedical chromatography : BMC
2024 · study · Temporal status not established
Nature communications
2024 · study · Temporal status not established
Nature communications
2025 · study · Temporal status not established
Reproduction in domestic animals = Zuchthygiene
2025 · study · Temporal status not established
Neurotoxicology
2025 · study · Temporal status not established
Biomolecules
2026 · regulatory · Temporal status not established
European Union
2026 · regulatory · Temporal status not established
United States
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
2 represented evidence records
Years represented: 2022, 2023
Publishing organizations appearing in records: JCI insight, The Journal of pathology
2 represented evidence records
Years represented: 2022, 2023
Publishing organizations appearing in records: JCI insight, The Journal of pathology
2 represented evidence records
Years represented: 2022, 2023
Publishing organizations appearing in records: JCI insight, The Journal of pathology
1 represented evidence record
Years represented: 2018
Publishing organizations appearing in records: The Journal of endocrinology
1 represented evidence record
Years represented: 2018
Publishing organizations appearing in records: Molecules (Basel, Switzerland)
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 6 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Kisspeptin-10 evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union
Regulator: Not represented
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
United States
Regulator: Not represented
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:25:56 AM
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
PubMed-indexed english abstract; journal article examining [not available]. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining kisspeptin-10 binding to gpr54 in osteoclasts prevents bone loss by activating dusp18-mediated dephosphorylation of src. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed published erratum examining author correction: kisspeptin-10 binding to gpr54 in osteoclasts prevents bone loss by activating dusp18-mediated dephosphorylation of src. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining stimulation of growth hormone by kisspeptin antagonists in ewes. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining effects of kisspeptin-10 on the reproductive performance of sows in a fixed-time artificial insemination programme. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining kisspeptin-10 increases collagen content in the myocardium by focal adhesion kinase activity. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining kisspeptin-10 in cryodiluent improves the post-thaw quality of nili-ravi buffalo (bubalus bubalis) bull spermatozoa. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, n.i.h., extramural examining kisspeptins inhibit human airway smooth muscle proliferation. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining new insights in bovine follicular cysts. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining kisspeptin-10 protects against hiv-1 tat-induced blood-brain barrier dysfunction and neuroinflammation via rhoa/rock pathway: implications for hand therapy. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining effects of kisspeptin-10 on hypothalamic neuropeptides and neurotransmitters involved in appetite control. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed comparative study; journal article examining mechanistic insights into the more potent effect of kp-54 compared to kp-10 in vivo. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining hypothalamic-pituitary-ovarian axis reactivation by kisspeptin-10 in hyperprolactinemic women with chronic amenorrhea. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining kisspeptin-10 (kp-10) stimulates osteoblast differentiation through gpr54-mediated regulation of bmp2 expression and activation. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, n.i.h., extramural examining kisspeptin regulates airway hyperresponsiveness and remodeling in a mouse model of asthma. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining the effects of kisspeptin-10 on serum metabolism and myocardium in rats. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining kisspeptin-10 ameliorates obesity-diabetes with diverse effects on ileal enteroendocrine cells and pancreatic islet morphology in high-fat fed female mice. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining kisspeptin-10 potentiates miniature excitatory postsynaptic currents in the rat supraoptic nucleus. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining kisspeptin-10 rescues cholinergic differentiated shsy-5y cells from α-synuclein-induced toxicity in vitro. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining mutual interactions between gnrh and kisspeptin in gnrh- and kiss-1-expressing immortalized hypothalamic cell models. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining kisspeptin-10 inhibits the migration of breast cancer cells by regulating epithelial-mesenchymal transition. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining the effects of kisspeptin-10 on migration and proliferation of endothelial cell. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining kisspeptin-10 promotes progesterone synthesis in bovine ovarian granulosa cells via downregulation of microrna-1246. Machine-staged source candidate; findings and limitations require accountable review before publication.
1 represented evidence record
Years represented: 2021
Publishing organizations appearing in records: Reproductive sciences (Thousand Oaks, Calif.)
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: Reproduction in domestic animals = Zuchthygiene
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: Biomolecules
1 represented evidence record
Years represented: 2018
Publishing organizations appearing in records: Molecules (Basel, Switzerland)
1 represented evidence record
Years represented: 2025
Publishing organizations appearing in records: Reproduction in domestic animals = Zuchthygiene
1 represented evidence record
Years represented: 2018
Publishing organizations appearing in records: Molecules (Basel, Switzerland)
1 represented evidence record
Years represented: 2017
Publishing organizations appearing in records: PloS one